Date: 2012-11-05
Type of information: R&D agreement
Compound: portfolio of clinical, preclinical and research assets
Company: Ziarco (UK) Pfizer (USA - NY)
Therapeutic area: Allergic diseases - Immunological diseases - Inflammatory diseases
Type agreement: R&D
licensing
commercialisation
Action mechanism:
Disease:
Details: Ziarco, a newly created clinical-stage biotechnology company, has entered into an agreement with Pfizer for the exclusive worldwide rights to commercialize a portfolio of clinical, preclinical and research assets. In return, Pfizer will receive equity as well as certain product-based milestone and royalty payments. Ziarco’s pipeline includes a histamine H4 receptor antagonist programme, with a lead compound that has completed a Phase 1 multiple ascending dose study; a clinical stage cytosolic phosholipase A2 (cPLA2) inhibitor; histamine H3 receptor antagonists possessing CNS-sparing properties, with a lead compound in advanced preclinical development; as well as early-stage spleen tyrosine kinase (SYK) inhibitor molecules suitable for topical administration.
The most advanced clinical programme is a histamine H4 receptor (H4R) antagonist, ZPL-3893787, which could potentially be used to treat several major diseases, including asthma, allergic rhinitis, pain and a variety of inflammatory skin conditions. A second clinical-stage programme targets inflammatory disorders by inhibiting cytosolic phosholipase A2 (cPLA2). The pipeline is completed by a histamine H3 receptor antagonist programme possessing CNS-sparing properties which is in advanced preclinical development and an early-stage spleen tyrosine kinase (SYK) inhibitor programme suitable for topical administration.
Financial terms:
Latest news:
